|
Volumn 3, Issue 1, 2005, Pages 10-11
|
Meningococcal meningitis
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CHLORAMPHENICOL;
MEMBRANE PROTEIN;
MENINGOCOCCUS TYPE A VACCINE;
MENINGOCOCCUS TYPE C VACCINE;
MENINGOCOCCUS VACCINE;
PENICILLIN G;
POLYSACCHARIDE;
POLYSACCHARIDE VACCINE;
UNCLASSIFIED DRUG;
ACCURACY;
ANTIBIOTIC SENSITIVITY;
ANTIGENIC VARIATION;
BACTERIAL COLONIZATION;
BACTERIAL TRANSMISSION;
BACTERIUM IDENTIFICATION;
CLINICAL TRIAL;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG COST;
EPIDEMIC MENINGITIS;
FEVER;
GEOGRAPHIC DISTRIBUTION;
HEADACHE;
HEALTH CARE ACCESS;
HEALTH CARE POLICY;
HUMAN;
IMMUNOGENICITY;
IMMUNOLOGICAL MEMORY;
INCIDENCE;
INFECTION CONTROL;
INTERNATIONAL COOPERATION;
MENINX;
MULTILOCUS ENZYME ELECTROPHORESIS;
MULTILOCUS SEQUENCE TYPING;
NEISSERIA MENINGITIDIS;
NOTE;
PRIORITY JOURNAL;
RIGIDITY;
SEROLOGY;
UPPER RESPIRATORY TRACT;
AFRICA SOUTH OF THE SAHARA;
CLINICAL TRIALS;
HUMANS;
INCIDENCE;
INFANT;
MENINGITIS, MENINGOCOCCAL;
MENINGOCOCCAL VACCINES;
VACCINATION;
VACCINES, CONJUGATE;
WORLD HEALTH;
BACTERIA (MICROORGANISMS);
NEISSERIA;
NEISSERIA MENINGITIDIS;
|
EID: 19944390166
PISSN: 17401526
EISSN: None
Source Type: Journal
DOI: 10.1038/nrmicro1070 Document Type: Note |
Times cited : (4)
|
References (14)
|